ARTICLE | Company News
Five Prime cuts headcount by 20%
January 18, 2019 7:00 PM UTC
Five Prime Therapeutics Inc. (NASDAQ:FPRX) said it will reduce headcount by 41 (20%). Cuts will come from research, pathology and manufacturing.
The cancer company’s pipeline includes five programs. Its lead compound, bemarituzumab, is in Phase III to treat gastric cancer...
BCIQ Company Profiles